• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌切除术时下腔静脉血栓的保守治疗。

Conservative management of inferior vena cava thrombus during nephrectomy for renal cell carcinoma.

机构信息

Department of Urology, Strasbourg University Hospital, Strasbourg, France.

Department of Urology, Strasbourg University Hospital, Strasbourg, France.

出版信息

Urol Oncol. 2024 Dec;42(12):452.e21-452.e28. doi: 10.1016/j.urolonc.2024.08.018. Epub 2024 Sep 14.

DOI:10.1016/j.urolonc.2024.08.018
PMID:39278735
Abstract

OBJECTIVES

To assess the impact on survival outcomes of positive vascular margins (PVM) after nephrectomy, open thrombectomy and renal vein ostium resection without inferior vena cava (IVC) segmental resection for nonmetastatic clear cell renal cell carcinoma (ccRCC).

MATERIALS AND METHODS

Medical records of patients undergoing nephrectomy and open thrombectomy for ccRCC in 1 center were retrospectively reviewed. Baseline characteristics, pathological features and surgery parameters were collected. A Cox uni- and multivariate regression model was used to evaluate the association between common prognosis factors including PVM and survival outcomes.

RESULTS

Thirty-nine patients were included. Median age was 65 (55-74) years, mean tumor size was 101±35.7mm, 35/39 (89%) had an infra-diaphragmatic IVC thrombus, and on pathological examination 19 (49%) and 17 (44%) patients had a Fuhrman/ISUP grade 3 and grade 4 ccRCC, respectively, and 23 (59%) had PVM. The median overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) were 66, 116 and 28 months, respectively. In the univariate analysis, OS was significantly shorter in case of PVM (HR 4.21, P = 0.01), but there was no significative impact on CSS, local recurrence and DFS. In the multivariate analysis, PVM had no impact on OSS, CSS, local recurrence and DFS, but metastatic lymph nodes were associated with a higher risk of death (HR 4.37, P = 0.015), local recurrence (HR 9.98, P = 0.004) and disease progression (HR 6.09, P = 0.002) and a supra-diaphragmatic thrombus was associated with a higher risk of local recurrence (HR 13.83, P = 0.007) and disease progression (HR 7.77, P = 0.003).

CONCLUSION

In a population with a high rate of positive vascular margins, inferior vena cava wall invasion had a minimal impact on survival outcomes. This must be considered regarding the invasiveness of the surgery used for these patients.

摘要

目的

评估肾切除术、开放血栓切除术和肾静脉口切除术后阳性血管边缘(PVM)对非转移性透明细胞肾细胞癌(ccRCC)患者生存结果的影响。

材料和方法

回顾性分析 1 家中心行肾切除术和开放血栓切除术治疗 ccRCC 的患者病历。收集基线特征、病理特征和手术参数。使用 Cox 单变量和多变量回归模型评估包括 PVM 在内的常见预后因素与生存结果之间的关系。

结果

共纳入 39 例患者。中位年龄为 65(55-74)岁,平均肿瘤大小为 101±35.7mm,35/39(89%)患者下腔静脉有膈下血栓,病理检查显示 19(49%)和 17(44%)例患者的 Fuhrman/ISUP 分级为 3 级和 4 级 ccRCC,23(59%)例患者存在 PVM。中位总生存期(OS)、癌症特异性生存期(CSS)和无病生存期(DFS)分别为 66、116 和 28 个月。单因素分析显示,PVM 患者 OS 显著缩短(HR 4.21,P=0.01),但 CSS、局部复发和 DFS 无显著影响。多因素分析显示,PVM 对 OSS、CSS、局部复发和 DFS 无影响,但转移性淋巴结与死亡风险(HR 4.37,P=0.015)、局部复发(HR 9.98,P=0.004)和疾病进展(HR 6.09,P=0.002)风险增加相关,膈上血栓与局部复发(HR 13.83,P=0.007)和疾病进展(HR 7.77,P=0.003)风险增加相关。

结论

在血管边缘阳性率较高的人群中,下腔静脉壁侵犯对生存结果的影响较小。在考虑这些患者的手术侵袭性时,必须考虑这一点。

相似文献

1
Conservative management of inferior vena cava thrombus during nephrectomy for renal cell carcinoma.肾细胞癌切除术时下腔静脉血栓的保守治疗。
Urol Oncol. 2024 Dec;42(12):452.e21-452.e28. doi: 10.1016/j.urolonc.2024.08.018. Epub 2024 Sep 14.
2
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.细胞减灭性肾切除术治疗伴有静脉瘤栓的肾细胞癌。
J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.
3
Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.细胞减灭性肾切除术治疗下腔静脉肿瘤栓转移性肾细胞癌患者的肿瘤学结果。
Int J Clin Oncol. 2018 Jun;23(3):553-558. doi: 10.1007/s10147-017-1232-9. Epub 2018 Jan 13.
4
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.手术对接受 TKI 治疗的伴有 IVC 血栓的转移性肾细胞癌预后的影响。
J Surg Oncol. 2014 Aug;110(2):145-50. doi: 10.1002/jso.23612. Epub 2014 Apr 3.
5
Surgical management of renal cell carcinoma with inferior vena caval thrombus: a teaching hospital experience.伴有下腔静脉血栓的肾细胞癌的外科治疗:一家教学医院的经验
Indian J Cancer. 2007 Apr-Jun;44(2):45-50. doi: 10.4103/0019-509x.35810.
6
Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?肾细胞癌的外科治疗:计算机断层扫描或磁共振成像下腔静脉瘤栓的形态学特征能否作为预后因素?
Int J Urol. 2017 Feb;24(2):102-109. doi: 10.1111/iju.13272. Epub 2017 Jan 22.
7
Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance.伴有下腔静脉瘤栓的肾细胞癌肾静脉开口壁侵犯:通过肾静脉和腔静脉直径预测及预后意义
J Urol. 2008 Feb;179(2):450-4; discussion 454. doi: 10.1016/j.juro.2007.09.042.
8
Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium.国际肾细胞癌-静脉血栓形成联盟多机构分析:肾细胞癌合并肿瘤栓子患者肾静脉或下腔静脉镜下壁侵犯对癌症特异性生存的影响。
Eur Urol Focus. 2018 Apr;4(3):435-441. doi: 10.1016/j.euf.2017.01.009. Epub 2017 Feb 9.
9
Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience.中国肾细胞癌伴静脉瘤栓延伸患者的临床和肿瘤学结局:单中心经验
World J Surg Oncol. 2015 Feb 4;13:14. doi: 10.1186/s12957-015-0448-2.
10
A Predictive Model for Tumor Invasion of the Inferior Vena Cava Wall Using Multimodal Imaging in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus.基于多模态影像的肾细胞癌合并下腔静脉瘤栓患者下腔静脉壁肿瘤侵犯预测模型。
Biomed Res Int. 2020 Oct 6;2020:9530618. doi: 10.1155/2020/9530618. eCollection 2020.